glp 1 and parkinson's disease Proposed mechanisms underpinning the beneficial neurological action of glp 1 neuroprotection Beyond insulin:

and Volek, J

Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy

Contraindications : People with heart disease, arrhythmias, uncontrolled high blood pressure, overactive thyroid, glaucoma, agitation, a history of substance use disorder, or recent MAOI use

However, the weight loss induced by GLP-1R mono-therapies in obese T2DM patients is modest indicating a need for more robust therapeutic options

Drug Intell

However, many people misunderstand an important detail: Melanotan peptides usually still require some UV exposure to produce visible tanning effects